Table 1. Baseline characteristics of the genotyped participants of European ancestry in the selected studies.
| Study | Source | N | Men (%) | Age (SD, SE), years | Aβ40 (SD, SE), pg/ml | Aβ42 (SD, SE), pg/ml | Tau (SD, SE), pg/ml | pTau (SD, SE), pg/ml |
| ARIC | Plasma | 1560 | 723 (46.3) | 77.4 (5.4, 0.1) | 247.0 (84.5, 2.1) | 39.1 (11.2, 0.3) | NA | NA |
| FHS_C1 | Plasma | 636 | 227 (35.7) | 79.8 (4.2, 0.2) | 168.3 (41.9, 1.7) | 45.4 (11.5, 0.5) | 5.0 (1.5, 0.1) | NA |
| FHS_C2 | Plasma | 3095 | 1443 (46.6) | 61.0 (9.5, 0.2) | 159.6 (40.5, 0.8) | 43.7 (10.3, 0.7) | 4.2 (2.7, 0.1) | NA |
| FHS_C3 | Plasma | 3029 | 1424 (47.0) | 45.7 (8.0, 0.1) | 242.5 (58.0, 1.1) | 42.7 (10.0, 0.2) | 4.1 (1.5, 0.02) | NA |
| ADNI-1 | Plasma | 612 | 374 (61.1) | 75.4 (6.7, 0.3) | 152.9 (50.5, 2.0) | 37.2 (11.3, 0.5) | 2.9 (1.6, 0.1) | NA |
| ADNI-1 | CSF | 350 | 212 (60.6) | 74.9 (7.1, 0.4) | 7737.3 (2352.3, 125.7) | 769.0 (352.0, 18.9) | 302.3 (118.4, 6.3) | 29.7 (13.6, 0.7) |
| ADNI-2/GO | CSF | 360 | 203 (56.4) | 72.9 (7.4, 0.4) | 8590.2 (2437.7, 130.1) | 920.6 (368.2, 19.4) | 271.6 (118.6, 6.3) | 25.7 (13.1, 0.7) |
N denotes the number of subjects; Abbreviations: CSF: cerebrospinal fluid; SD: standard deviation; SE: standard error; NA: not available. ARIC is the Atherosclerosis Risk in Communities Study; FHS_C1, FHS_C2, and FHS_C3 denote the Framingham Heart Study parental, offspring, and grandchildren cohorts, respectively; ADNI-1 and ADNI-2/GO denote the Alzheimer’s disease Neuroimaging Initiative initial and extended cohorts, respectively. Age was defined at the time of the Alzheimer’s disease biomarker measurement.